|1.||Goulart, Isabela Maria Bernardes: 4 articles (12/2015 - 12/2004)|
|2.||Goulart, Luiz Ricardo: 3 articles (12/2015 - 12/2004)|
|3.||Sharma, P: 3 articles (06/2000 - 06/2000)|
|4.||Kaur, H: 3 articles (06/2000 - 06/2000)|
|5.||Kar, H K: 3 articles (06/2000 - 06/2000)|
|6.||Rani, R: 3 articles (06/2000 - 06/2000)|
|7.||Mukherjee, R: 3 articles (06/2000 - 06/2000)|
|8.||Misra, R S: 3 articles (06/2000 - 06/2000)|
|9.||Mukherjee, A: 3 articles (06/2000 - 06/2000)|
|10.||Ferreira, Frederico Rogério: 2 articles (10/2006 - 12/2004)|
|1.||Leprosy (Hansen's Disease)
01/01/1966 - "The conclusion is reached that the anergic, or factor N, hypothesis that has been evolved to relate the lepromin test to the findings in clinical leprosy appears to be the most promising, and that, if this hypothesis can be substantiated, it is unlikely that BCG vaccination can be a very useful tool for prevention. "
07/01/1975 - "With the significant information compiled in this study, it is concluded that lepromin prepared from bacilli obtained from infected armadillos is as effective as that prepared from bacilli obtained from the lesions of leprosy patients."
09/01/1999 - "The lepromin response evaluated in terms of percentage of subjects converting to positivity status, measurement in millimeters, and duration of lepromin positivity sustained, reflected a statistically significant better outcome in the vaccine group patients (especially LL and BL leprosy) in comparison to those in the placebo group. "
07/01/1996 - "The findings in the study showed specific unresponsiveness to lepromin in LMI in leprosy contacts of less than two years duration, direct contacts, contacts of lepromatous spectrum of index patients and contacts not vaccinated with B.C.G. "
03/01/1994 - "In this study, we measured in vitro proliferative responses of peripheral blood mononuclear cells from both leprosy patients across the clinical spectrum and also healthy contacts from a leprosy-endemic population to delipidified cell components of Mycobacterium leprae (DCC) and Dharmendra lepromin. "
03/01/1988 - "The administration of a vaccine containing ICRC bacilli, which is currently undergoing clinical trials in India, induces persistent lepromin conversion in lepromatous leprosy (LL) patients and lepromin-negative healthy subjects, with "upgrading" of tissue response in the former. "
11/01/2006 - "The diagnosis, based on clinical suspicion, is confirmed through bacteriological and histopathological analyses, as well as by means of the lepromin test (intradermal reaction that is usually negative in lepromatous leprosy form and positive in the tuberculoid form). "
09/01/2005 - "The finding of Mitsuda positivity in histopathologically proven polar lepromatous leprosy is extremely uncommon, and conversion of lepromin status following MDT has not so far been reported. "
06/01/2001 - "Vaccination induced lepromin conversion in 100% of lepromatous leprosy cases and lepromin negative household contacts and augmentation of lepromin reactivity in 100% of lepromin positive household contacts, which was stable for the 15 weeks duration of follow-up. "
01/01/1994 - "Slit-skin smears and histopathology from the lesions proved the diagnosis to be lepromatous leprosy with a bacterial index (BI) 6+. The initial lepromin test was negative. "
12/01/1983 - "leprae induced a highly persistent state of lepromin hypersensitivity which was quantitatively superior to that observed in animals sensitized with the three other mycobacteria."
10/01/1977 - "Immediate-type hypersensitivity response to Mitsuda lepromin component."
02/01/1969 - "Passive transfer of hypersensitivity to lepromin."
09/01/1957 - "[Lepromin allergy in BCG vaccinated leprous patients]."
12/01/2009 - "Induction of lepromin reactivity in cured lepromatous leprosy patients: impaired chemokine response dissociates protective immunity from delayed type hypersensitivity."
06/01/1995 - "We report a 5-year follow-up study of healthy children who were close contacts of leprosy patients, in order to: 1. detect subclinical infection and observe the development of overt disease by using the Fluorescent Leprosy Antibody Absorption Technique (FLA-ABS) and the lepromin test which assess the humoral and cell-mediated immunity (CMI), respectively; 2. evaluate the efficacy of dapsone as a chemoprophylactic agent in the 'at risk' contacts. "
07/01/1980 - "leprae, recent studies indicate that a certain number of contacts who develop sub-clinical infection remain anergic to the lepromin test. "
10/01/1985 - "Repeated lepromin testing had no effect in the rate of infection and the course of the disease in animals infected intravenously. "
09/01/1983 - "Eight armadillos resistant to the infection of Mycobacterium leprae were lepromin tested. "
06/01/1982 - "It is suggested that by using the lepromin response it is possible to assess, to a great extent, the susceptibility of armadillos to infection by M. "
06/01/1982 - "In this preliminary report the histopathological appearance of the lepromin reaction in armadillos was correlated with their response to infection with M. "
|7.||Immunoglobulin M (IgM)
|10.||Immunoglobulin G (IgG)
|3.||Drug Therapy (Chemotherapy)